Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Drug Deliv. 2011 Jun;8(6):833-9. doi: 10.1517/17425247.2011.581658. Epub 2011 May 8.

The redesigned follitropin α pen injector for infertility treatment.

Author information

1
Merck Serono S.A., Geneva, Switzerland.

Abstract

INTRODUCTION:

Treatment for infertility may require multiple drugs and complex dosing schedules. Available injection devices for patients who require regular injections during treatment are reviewed in this article, focusing on pen injectors used to self-administer recombinant human follicle-stimulating hormone (follitropin α). Following the introduction of the first and second follitropin α pen injectors in the last decade, a third pen injector with improved design for the administration of follitropin α has been developed for use in fertility treatment cycles.

AREAS COVERED:

This paper presents the results of the dose accuracy testing with this pen injector that was performed in accordance with international standards (EN ISO 11608-1:2000). This overview also provides an understanding of the key features of the redesigned pen injector that are of interest to healthcare professionals.

EXPERT OPINION:

The availability of an improved injection device for the delivery of follitropin α used during infertility treatment cycles of ovulation induction and assisted reproductive technology offers patients and healthcare professionals new treatment administration options. As fertility treatment cycles involve the use of several injectable gonadotropins, a standard device that could be used for all such treatments would simplify both the administration and the teaching of administration considerably.

PMID:
21548843
DOI:
10.1517/17425247.2011.581658
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center